Evidence-based guideline for risk assessment, prophylaxis, diagnosis, and treatment of venous thromboembolism in cancer patients, including catheter-related thrombosis.
A comprehensive, evidence-based clinical guideline for the risk assessment, prevention, diagnosis, and treatment of venous thromboembolism (VTE) in patients with cancer, including deep vein thrombosis (DVT), pulmonary embolism (PE), and central venous access device (CVAD)-related thrombosis.
Cancer-associated thrombosis (CAT) is the second leading cause of death in patients with cancer after the malignancy itself. Patients with cancer face a four- to seven-fold increased risk of VTE compared with the general population, and this risk is further amplified by surgery, hospitalization, systemic anticancer therapy, and the presence of central venous access devices. The clinical management of thrombosis in cancer patients requires specialized approaches that balance the high recurrence risk against elevated bleeding risk, account for drug interactions with anticancer agents, and address unique situations including thrombocytopenia, brain metastases, gastrointestinal malignancies, and catheter-related events.1
This guideline synthesizes recommendations from six major evidence-based sources published between 2021 and 2024, rewritten in original language for clinical reference. It covers the full spectrum of cancer-associated VTE management from pathophysiology and risk stratification through acute treatment, long-term anticoagulation, and management of special populations.2 3 4 5 6 7
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Pathophysiology and Risk Assessment | Virchow’s triad in cancer, tumor procoagulant mechanisms, validated risk assessment models (Khorana, Vienna CATS, PROTECHT, ONKOTEV), complete scoring tables |
| Part 2 | VTE Prophylaxis in Cancer Patients | Ambulatory prophylaxis, hospitalized patient prophylaxis, surgical thromboprophylaxis, CVAD-related thrombosis prevention |
| Part 3 | Treatment of Established Cancer-Associated VTE | Initial anticoagulation, LMWH protocols, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin, duration of therapy, landmark trial data |
| Part 4 | Special Situations and Populations | Brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, IVC filters |
| Part 5 | CVAD-Related Thrombosis Management and Patient Education | Catheter-related upper extremity DVT diagnosis and treatment, catheter management decisions, patient education, monitoring, and follow-up |
This guideline synthesizes and restates in original language the clinical recommendations from multiple major professional society guidelines and evidence-based sources on cancer-associated thrombosis published between 2021 and 2024. No proprietary guideline text is reproduced. All clinical data, trial results, and dosing parameters referenced herein are drawn from published peer-reviewed literature. ↩︎
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41(16):3063-3071. ↩︎
Falanga A, Palumbo JS, Rickles FR, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(4):371-389. ↩︎
Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. ↩︎
Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545-e608. ↩︎
Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891-1894. Updated guidance 2022. ↩︎
National Comprehensive Cancer Network. Cancer-Associated Venous Thromboembolic Disease, Version 1.2024. NCCN Clinical Practice Guidelines in Oncology. ↩︎
Comprehensive management of central venous access device-related thrombosis including diagnosis, treatment, catheter management decisions, upper extremity DVT, patient education, monitoring, and follow-up.
Management of cancer-associated VTE in special populations including brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, and IVC filter indications.
Complete treatment protocols for cancer-associated VTE including LMWH dosing, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin considerations, duration of anticoagulation, and landmark trial data from SELECT-D, HOKUSAI-VTE Cancer, ADAM-VTE, and CARAVAGGIO.
Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.
Pathophysiology of cancer-associated thrombosis, Virchow's triad in malignancy, and validated VTE risk assessment models including the Khorana score, Vienna CATS score, PROTECHT score, and ONKOTEV score with complete scoring tables.